Moderna Inc. (MRNA) Stock — Today's Move

MRNA is likely to face a key Q2 test as investors await results, FDA updates on mRNA-1010 and commercialization plans that could shape its post-COVID growth.

Moderna stock has delivered a strong 70.9% gain over the past year, but the longer track record and current valuation checks suggest the shares are not clearly priced as a bargain…

The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 billion in the first half of the year, the highest tot…

In recent months, Moderna reported a very large year-on-year Q1 revenue increase that surpassed analyst expectations, secured two European approvals including the world’s first fl…

FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.